Jim Cramer’s Second defensive stock on CNBC’s MAD MONEY in medical devices as a portfolio of last resort is Becton Dickinson (BDX). It is a safe traditional medical device and diagnostics company. They even invented a longer needle because of Americans getting fatter and needing longer needles. The Genome and Tripath acquisitions are going great and they are into screening for cancer. It is up 31% since he first recommended it in July, but their increased guidance will drive this stock higher. The analysts are 4 buys and holds, so he thinks that ratio of 2:1 analysts being negative will create upgrades and the company will be able to beat estimates. Cramer thinks the analysts are holding back so they can cover other names.
Jon C. Ogg
April 30, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.